Daiwa Securities Initiates Coverage on HUTCHMED With Buy Rating, $23 Price Target

MT NewswiresDec 19 20:40 · Ratings

Express News | Ping An Securities Pharmaceutical Industry 2025 Annual Strategy Report: Exploring new growth from payment sources, focusing on innovation, going overseas, equipment upgrades, and Consumer recovery.

BreakingsDec 15 12:17

HUTCHMED (China) to Receive $10 Million Milestone Payment From Takeda After First European Reimbursement for Fruzaqla

MT NewswiresDec 13 12:23

Hutchmed (China) (00013.HK) will receive a milestone payment of 10 million dollars from its partner.

Hutchmed (China) (00013.HK) announced that it will receive a milestone payment of $10 million from its partner Takeda (TAK.US). Takeda secured FRUZAQLA in Spain this December for treatment recommendations of previously treated metastatic colorectal cancer patients to be included in the public medical insurance coverage, marking the first recommendation for such inclusion in Europe. The announcement stated that FRUZAQLA received approval from the European Commission in June this year. Takeda holds the global exclusive rights for further development, commercialization, and production of furmonertinib outside of mainland China, Hong Kong, and Macau.

AASTOCKSDec 13 08:23

Hutchmed (China) (00013.HK): Following the first inclusion of FRUZAQLA (fruquintinib) in the healthcare insurance in Europe, a milestone payment from Takeda will be received.

Gelonghui reports on December 13 that Hutchmed (China) (00013.HK) announced it will receive a $10 million milestone payment from its partner Takeda (TSE: 4502/NYSE: TAK). Takeda has received a recommendation in December 2024 for FRUZAQLA to be included in public medical coverage for patients with previously treated metastatic colorectal cancer in Spain, marking the first recommendation for public medical coverage obtained in Europe. Colorectal cancer is the second leading cause of cancer-related deaths in Europe. FRUZAQLA received approval from the European Commission in June 2024.

Gelonghui FinanceDec 13 08:04

Reported Earlier, HUTCHMED's ORPATHYS and TAGRISSO Combo Gains Therapy Designation in China for Advanced Lung Cancer

BenzingaDec 12 15:15